Company Morale

Quote

anonymous

Guest
Serious question - how is the morale at Heron in the field and overall?

This board is surprisingly quiet for a company that has struggled and failed so much over the last several years.

Are people just resigned to it all now, or are they leaving or actually believing there is a future?

And what about company direction wrt partner or sale of the company? Feels like a zombie company with bad leadership and no activist interest to change the storyline here.

Any thoughts from staff here or have you all just given up?
 












Heron Reps in our region seem very positive about the launch. Have been hearing good anecdotal results early on. Reimbursement is great especially for HOPD and ASC patients. With the push for more same day discharges and need for opioid alternatives seems like an easy sell in this environment. Zynrelef is actually profitable for HOPD/ASC facilities which will make the life of the rep easy having a cost neutral or profitable product that improves patient outcomes minimizing opioids in the midst of the opioid epidemic.

Just received our first shipment of Zynrelef at our institution.
 






Calling BS on above post. I’m not hearing anything like that! Locked out due to COVID restrictions and no one willing to review at P&T due to bigger priorities.
Please don’t create false narratives, not helpful.
 






anonymous said:
Calling BS on above post. I’m not hearing anything like that! Locked out due to COVID restrictions and no one willing to review at P&T due to bigger priorities.
Please don’t create false narratives, not helpful.
Click to expand...

We’ll see. We all know formulary status doesn’t happen overnight. Pacira created a bad taste in everyone’s mouth with bad pharmacy relations, over promising and under delivering on efficacy and duration, and all the bad data out there. This is a marathon not a sprint and it’s no secret Pacira reps know they’re going to lose infiltration business. Z is a superior product in many ways, Ex still has a place in nerve block.
 






anonymous said:
We’ll see. We all know formulary status doesn’t happen overnight. Pacira created a bad taste in everyone’s mouth with bad pharmacy relations, over promising and under delivering on efficacy and duration, and all the bad data out there. This is a marathon not a sprint and it’s no secret Pacira reps know they’re going to lose infiltration business. Z is a superior product in many ways, Ex still has a place in nerve block.
Click to expand...

"This is a marathon, not a sprint" ain't exactly true here. Not when Heron is burning 40-50 million dollars a quarter and has only 250 million or so in the bank. Also bear in mind that the CINV business isn't profitable today, isn't recovering very well from covid headwinds, and there is otherwise no real indication there will be a sales inflection anytime soon. Heron overhired on the sales front to launch Zynrelef, unfortunately into a tough market due to a delta-driven covid resurgence; maybe this was just bad luck or maybe a slow sales ramp was inevitable anyway. Either way, BQ put a promise out there that Zynrelef will outsell Exparel in its first six quarters on the market. Looking more likely than not that he'll eat those words, losing further credibility in the process. And all along the way, Heron will be burning through hundreds of millions of dollars the next two years, raising the concern if the company will have the finances to even come close to "finishing the marathon", alluding to what you say. In that light, no, I don't think this is a marathon, I very much think it's a sprint. This is not a company that has the luxury of time on its hand; not after fumbling through two CRLs on Zynrelef further delaying a market entry. So get out and sell or you may not have a job by the end of next year.
 






anonymous said:
"This is a marathon, not a sprint" ain't exactly true here. Not when Heron is burning 40-50 million dollars a quarter and has only 250 million or so in the bank. Also bear in mind that the CINV business isn't profitable today, isn't recovering very well from covid headwinds, and there is otherwise no real indication there will be a sales inflection anytime soon. Heron overhired on the sales front to launch Zynrelef, unfortunately into a tough market due to a delta-driven covid resurgence; maybe this was just bad luck or maybe a slow sales ramp was inevitable anyway. Either way, BQ put a promise out there that Zynrelef will outsell Exparel in its first six quarters on the market. Looking more likely than not that he'll eat those words, losing further credibility in the process. And all along the way, Heron will be burning through hundreds of millions of dollars the next two years, raising the concern if the company will have the finances to even come close to "finishing the marathon", alluding to what you say. In that light, no, I don't think this is a marathon, I very much think it's a sprint. This is not a company that has the luxury of time on its hand; not after fumbling through two CRLs on Zynrelef further delaying a market entry. So get out and sell or you may not have a job by the end of next year.
Click to expand...

BQ has no credibility left to lose.
 






anonymous said:
"This is a marathon, not a sprint" ain't exactly true here. Not when Heron is burning 40-50 million dollars a quarter and has only 250 million or so in the bank. Also bear in mind that the CINV business isn't profitable today, isn't recovering very well from covid headwinds, and there is otherwise no real indication there will be a sales inflection anytime soon. Heron overhired on the sales front to launch Zynrelef, unfortunately into a tough market due to a delta-driven covid resurgence; maybe this was just bad luck or maybe a slow sales ramp was inevitable anyway. Either way, BQ put a promise out there that Zynrelef will outsell Exparel in its first six quarters on the market. Looking more likely than not that he'll eat those words, losing further credibility in the process. And all along the way, Heron will be burning through hundreds of millions of dollars the next two years, raising the concern if the company will have the finances to even come close to "finishing the marathon", alluding to what you say. In that light, no, I don't think this is a marathon, I very much think it's a sprint. This is not a company that has the luxury of time on its hand; not after fumbling through two CRLs on Zynrelef further delaying a market entry. So get out and sell or you may not have a job by the end of next year.
Click to expand...
 







What do you expect when you recruit trash from pacira and recycle it- You can dress a pig up and put lipstick on it and it is still a pig. Look at all the award winners we brought over, most of these detailers were on plan or never made it to the show- I told them not to bring these dead woods over. How is that superstar national accounts person doing from exparel
 












anonymous said:
"Same as it ever was, same as it ever was...."
Talking Heads

She was part of the most ineffective department at Pacira. The IDN team did nothing. To their credit, they did nothing well.
Click to expand...

Joey Terry did! He is the superstar of accomplishing nothing in over 5 years. He should write a book "How to be relevant when your not"
 


















Top Bottom
Back
Quote